We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.51B
AUM Growth
+$203K
Cap. Flow
-$184M
Cap. Flow %
-4.08%
Top 10 Hldgs %
82.68%
Holding
115
New
24
Increased
20
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$15.8M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
3
MET icon
MetLife
MET
+$10.7M
4
TSRO
TESARO, Inc.
TSRO
+$8.14M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.5M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$41.4M
2
BLUE
bluebird bio
BLUE
+$13.6M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.9M
4
CELG
Celgene Corp
CELG
+$12M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.24M

Sector Composition

Rank Sector Weight
1 Consumer Staples 44.81%
2 Healthcare 28.52%
3 Consumer Discretionary 10.77%
4 Financials 0.73%
5 Industrials 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.01B 44.65%
87,460,875
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$825M 18.31%
57,517,977
– –
WW
3
DELISTED
WW International
WW
$458M 10.18%
29,443,300
– –
MET icon
4
CALL
MetLife
MET
$62.9B
$92.4M 2.05%
1,963,500
– –
BAC icon
5
CALL
Bank of America
BAC
$435B
$82.6M 1.83%
3,500,000
+1,900,000
+119% +$45.1M
GS icon
6
CALL
Goldman Sachs
GS
$292B
$68.9M 1.53%
+300,000
New +$72.4M
BMY icon
7
CALL
Bristol-Myers Squibb
BMY
$130B
$54.4M 1.21%
1,000,000
+200,000
+25% +$11M
WFC icon
8
CALL
Wells Fargo
WFC
$259B
$44.5M 0.99%
800,000
-200,000
-20% -$11.3M
AGIO icon
9
Agios Pharmaceuticals
AGIO
$2.1B
$43.8M 0.97%
750,000
– –
INCY icon
10
Incyte
INCY
$25.3B
$43.4M 0.96%
325,000
-325,000
-50% -$41.4M
GILD icon
11
CALL
Gilead Sciences
GILD
$166B
$34M 0.75%
+500,000
New +$35.2M
CELG
12
CALL
DELISTED
Celgene Corp
CELG
$31.1M 0.69%
250,000
-450,000
-64% -$53.9M
C icon
13
CALL
Citigroup
C
$216B
$29.9M 0.66%
+500,000
New +$29.6M
REGN icon
14
CALL
Regeneron Pharmaceuticals
REGN
$73.2B
$29.1M 0.65%
75,000
-105,000
-58% -$38.9M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$12B
$28.5M 0.63%
325,000
-25,000
-7% -$2.22M
BABA icon
16
Alibaba
BABA
$275B
$27M 0.6%
250,000
– –
NKTR icon
17
Nektar Therapeutics
NKTR
$2.31B
$23.5M 0.52%
66,667
– –
BLUE
18
DELISTED
bluebird bio
BLUE
$22.7M 0.5%
19,300
-13,320
-41% -$13.6M
ATH
19
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
$22.5M 0.5%
450,000
+50,000
+13% +$2.48M
AAL icon
20
CALL
American Airlines Group
AAL
$9.99B
$21.1M 0.47%
+500,000
New +$22.6M
XLRN
21
DELISTED
Acceleron Pharma
XLRN
$19.9M 0.44%
750,000
+600,000
+400% +$15.8M
META icon
22
CALL
Meta Platforms (Facebook)
META
$1.5T
$17.8M 0.39%
+125,000
New +$16.7M
JPM icon
23
CALL
JPMorgan Chase
JPM
$931B
$17.6M 0.39%
200,000
-400,000
-67% -$35.3M
IBM icon
24
CALL
IBM
IBM
$213B
$17.4M 0.39%
104,600
– –
BABA icon
25
CALL
Alibaba
BABA
$275B
$16.2M 0.36%
+150,000
New +$15.3M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2017 Portfolio in Review

As of Q1 2017, Artal Group held 115 positions worth $4.51B, up 0% from $4.5B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group withdrew a net $184M in Q1 2017, closing 20 positions and reducing 23 holdings. Its most notable exit was Celgene Corp, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 45% of assets, down from 47% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Ionis Pharmaceuticals worth $10.1M.

  • Artal Group's largest Q1 2017 buy was Ionis Pharmaceuticals: 250,000 shares worth $10.1M.
  • Artal Group added most to Acceleron Pharma in Q1 2017, an estimated $15.8M increase.
  • Artal Group's biggest Q1 2017 reduction was Incyte, cutting an estimated $41.4M.
  • Artal Group fully exited Celgene Corp in Q1 2017, selling an estimated $12M.
  • Artal Group's ten largest holdings make up 83% of its $4.51B portfolio in Q1 2017.
  • Artal Group opened 24 new positions and closed 20 in Q1 2017.
  • Artal Group's portfolio value rose 0% quarter-over-quarter to $4.51B.

Based on Artal Group's 13F filing for Q1 2017, filed 15 May 2017.